Overview

Clinical Study of Liposomal Paclitaxel in Chinese Patients

Status:
Unknown status
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the maximum tolerated dose and dose limiting toxicities of liposomal paclitaxel in Chinese patients with solid tumors in advanced stages.
Phase:
Phase 1
Details
Lead Sponsor:
Nanjing Sike Pharmaceutical Co., Ltd.
Treatments:
Albumin-Bound Paclitaxel
Paclitaxel